Loading... Please wait...

Categories

Our Newsletter


BMS-477118 (Saxagliptin) | DPP-IV inhibitor

  • BMS-477118 (Saxagliptin).jpg
  • BMS-477118 (Saxagliptin), 400x400px, png

Price:
$189.00
Catalog #:
C2477-5
Quantity:


Product Description

Saxagliptin is an orally-available, adamantyl-based, reversible inhibitor of DPP-IV for the treatment of Type 2 diabetes with an IC50 of 26 nM and Ki of 0.6-1.3 nM [1, 2]. Saxagliptin is more selective than other approved DPP-IV inhibitors (vildagliptin, sitagliptin) and is 400-fold and 75-fold selective over DPP-VIII and DPP-IX, respectively. [1] Once-daily administration of saxagliptin either as a monotherapy or in combination results in a significant reductions in fasting and postprandial plasma glucose and HbA1c.

Saxagliptin reduces the degradation of the incretin hormone glucagon-like peptide-1, improving b-cell function and suppression of glucagon secretion. [2]


Technical information:

Chemical Formula:   C18H25N3O2
CAS #:   361442-04-8
Molecular Weight:   315.41
Purity:   >98%
Appearance:   White
Chemical Name:   (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
Solubility:   Up to 22 mM in DMSO
Synonyms:   BMS-477118, BMS 477118, BMS477118, Saxagliptin, Onglyza

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Tahrani et al., Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv. Ther. 2009, 26(3), 249-262. Pubmed ID: 19330494
2. Deacon et al., Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv. Ther. 2009, 26(5), 488-499. Pubmed ID: 19444391

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Add to Wish List

Click the button below to add the BMS-477118 (Saxagliptin) | DPP-IV inhibitor to your wish list.

You Recently Viewed...